XENON PHARMACEUTICALS INC. (XENE) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -441.59M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 352.49M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-441.59M | (m) | (m) | $352.49M | (m) | (m) |
| 2026-03-31 | $-412.66M | (m) | (m) | $328.25M | (m) | (m) |
| 2025-12-31 | $-373.07M | (m) | (m) | $300.94M | (m) | (m) |
| 2025-09-30 | $-340.78M | (m) | (m) | $272.71M | (m) | (m) |
| 2025-06-30 | $-318.12M | (m) | (m) | $252.63M | (m) | (m) |
| 2025-03-31 | $-293.00M | (m) | (m) | $227.34M | (m) | (m) |
| 2024-12-31 | $-279.30M | (m) | (m) | $210.39M | (m) | (m) |
| 2024-09-30 | $-255.52M | (m) | (m) | $192.00M | (m) | (m) |
| 2024-06-30 | $-237.52M | (m) | (m) | $177.91M | (m) | (m) |
| 2024-03-31 | $-224.04M | (m) | (m) | $172.25M | (m) | (m) |
| 2023-12-31 | $-214.05M | (m) | (m) | $167.51M | (m) | (m) |
| 2023-09-30 | $-203.69M | (m) | (m) | $161.27M | (m) | (m) |
| 2023-06-30 | $-186.13M | (m) | (m) | $147.82M | (m) | (m) |
| 2023-03-31 | $-160.82M | (m) | (m) | $125.92M | (m) | (m) |
| 2022-12-31 | $-129.14M | (m) | (m) | $105.77M | (m) | (m) |
| 2022-09-30 | $-110.65M | (m) | (m) | $92.82M | (m) | (m) |
| 2022-06-30 | $-88.12M | (m) | (m) | $82.28M | (m) | (m) |
| 2022-03-31 | $-80.30M | (m) | (m) | $78.52M | (m) | (m) |
| 2021-12-31 | $-78.99M | (m) | (m) | $75.46M | (m) | (m) |
| 2021-09-30 | $-67.08M | (m) | (m) | $68.54M | (m) | (m) |
| 2021-06-30 | $-61.18M | (m) | (m) | $62.70M | (m) | (m) |
| 2021-03-31 | $-39.33M | (m) | (m) | $55.04M | (m) | (m) |
| 2020-12-31 | $-31.30M | (m) | (m) | $50.52M | (m) | (m) |
| 2020-09-30 | $-29.98M | (m) | (m) | $47.31M | (m) | (m) |
| 2020-06-30 | $-29.23M | (m) | (m) | $44.01M | (m) | (m) |
| 2020-03-31 | $-39.09M | (m) | (m) | $41.50M | (m) | (m) |
| 2019-12-31 | $-42.82M | (m) | (m) | $38.84M | (m) | (m) |
| 2019-09-30 | $-39.65M | (m) | (m) | $33.49M | (m) | (m) |
| 2019-06-30 | $-44.89M | (m) | (m) | $29.99M | (m) | (m) |
| 2019-03-31 | $-41.97M | (m) | (m) | $27.20M | (m) | (m) |
| 2018-12-31 | $-38.02M | (m) | (m) | $23.63M | (m) | (m) |
| 2018-09-30 | $-37.63M | (m) | (m) | $23.63M | (m) | (m) |
| 2018-06-30 | $-32.10M | (m) | (m) | $24.55M | (m) | (m) |
| 2018-03-31 | $-32.41M | (m) | (m) | $25.25M | (m) | (m) |
| 2017-12-31 | $-32.58M | $311.00K | (m) | $25.57M | (m) | -10474.28% |
| 2017-09-30 | $-29.99M | $671.00K | (m) | $23.57M | (m) | -4468.85% |
| 2017-06-30 | $-28.67M | $820.00K | (m) | $22.37M | (m) | -3496.71% |
| 2017-03-31 | $-27.15M | $1.22M | (m) | $21.37M | (m) | -2228.74% |
| 2016-12-31 | $-24.82M | $1.80M | (m) | $19.83M | (m) | -1376.43% |
| 2016-09-30 | $-21.96M | $4.65M | (m) | $19.70M | (m) | -471.81% |
| 2016-06-30 | $-15.45M | $8.54M | (m) | $17.52M | (m) | -180.98% |
| 2016-03-31 | $-8.88M | $12.17M | (m) | $16.09M | (m) | -72.99% |
| 2015-12-31 | $-9.36M | $15.58M | (m) | $15.15M | (m) | -60.10% |
| 2015-09-30 | $-6.72M | $17.23M | (m) | $14.34M | (m) | -39.02% |
| 2015-06-30 | $2.76M | $26.13M | (m) | $13.77M | (m) | 10.56% |
| 2015-03-31 | $8.87M | (m) | (m) | $12.66M | (m) | (m) |
| 2014-12-31 | $11.11M | $28.37M | (m) | $11.77M | (m) | 39.15% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $10.95M | $26.67M | (m) | (m) | (m) | 41.05% |
| 2014-03-31 | $8.80M | $26.97M | (m) | (m) | (m) | 32.63% |
| 2013-12-31 | $9.71M | $27.36M | (m) | $12.30M | (m) | 35.50% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-3.15M | $14.31M | (m) | $10.46M | (m) | -22.04% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |